Rob Etherington, Clene CEO

Star­tup's gold nanocrys­tal ALS drug flops a PhII tri­al, a re­minder of the dis­ease's ob­sta­cles de­spite Amy­lyx OK

De­spite the FDA ap­prov­ing an ALS drug for the first time in five years last week, the dis­ease con­tin­ues to flus­ter re­searchers, and an­oth­er biotech is feel­ing the pain of a mid-stage fail­ure.

Clene Nanomed­i­cine re­port­ed ear­ly Mon­day that its ALS pro­gram, which us­es gold nanocrys­tals to try to cat­alyze in­tra­cel­lu­lar re­ac­tions, did not achieve its Phase II pri­ma­ry or sec­ondary end­points. And in a press re­lease, the com­pa­ny not­ed for the first time that it’s speak­ing with “po­ten­tial strate­gic part­ners” about the pro­gram — lan­guage that typ­i­cal­ly in­di­cates a biotech is prepar­ing to sell off an as­set.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.